Pfizer buys migraine partner Biohaven for $11.6 B, betting on CGRP drugs in grand return to neuroscience – FiercePharma

  1. Pfizer buys migraine partner Biohaven for $11.6 B, betting on CGRP drugs in grand return to neuroscienceFirePharma
  2. Pfizer to buy biotech group Biohaven for $11.6bnFinancial Times
  3. Pfizer to spend $11.6B on migraine treatment maker BiohavenThe Independent
  4. Biohaven Pharmaceuticals shares surge after Pfizer agrees to acquire companyCNBC Television
  5. Pfizer Pays $11.6 Billion for Drug-Maker in Its Biggest Deal Since 2016Entrepreneur
  6. View Full coverage on Google News

.

Leave a Comment

Your email address will not be published.